Effectiveness of atypical antipsychotics for substance use in schizophrenia patients

Schizophrenia Research

Volumn 94, Issue 1-3, 2007, Pages 114-118

  Swanson, Jeffrey ^a   Van Dorn, Richard A ^b   Swartz, Marvin S ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Medication; Schizophrenia; Substance use

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NATURAL SCIENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURED INTERVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY; FOLLOW-UP STUDIES; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 34447107937     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.05.007     Document Type: Article

References (33)

1. Bellack A.S., and DiClemente C.C. Treating substance abuse among patients with schizophrenia. Psychiatric Services 50 (1999) 75-80
2. Buckley P.F. New antipsychotic agents: emerging clinical profiles. Journal of Clinical Psychiatry 60 (1999) 12-17
3. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60 (2003) 553-564
4. Diggle P.J., Liang K.-Y., and Zeger S.L. Analysis of Longitudinal Data (1994), Clarendon Press, Oxford
5. Drake R.E., Mueser K.T., and McHugo G.J. Clinical rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In: Sederer L.I., and Dickey B. (Eds). Outcomes Assessment in Clinical Practice (1996), Williams & Wilkins, Baltimore, MD 113-116
6. Drake R.E., Xie H., McHugo G.J., and Green A.I. The effects of Clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin 26 2 (2000) 441-449
7. Eli Lilly & Company. SCAP Health Questionnaire. Indianapolis, IN (1999)
8. Endicott J., Spitzer R., Fleiss J., and Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbances. Archives of General Psychiatry 33 (1976) 766s-771s
9. Goodman L.A., Salyers M.P., Mueser K., Rosenberg S.D., Swartz M.S., Essock S.M., Osher F.C., Butterfield M.I., Swanson J.W., Committee, and a. t. F.-S. H. a. R. S. R. Recent victimization in women and men with severe mental illness: prevalence and correlates. Journal of Traumatic Stress 14 4 (2001) 615-632
10. Green A.I. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. Journal of Clinical Psychiatry 66 (2005) 21-26
11. Green A.I., Strous R.D., Zimmet S.V., and Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard Review of Psychiatry 6 (1999) 287-296
12. Green M.F., Marshall Jr. B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., and Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. American Journal of Psychiatry 154 (1997) 799-804
13. Haywood T.W., Kravitz H.M., Grossman L.S., Cavanaugh J.L., Davis J.M., and Lewis D.A. Predicting the revolving-door phenomenon among patients with schizophrenic, schizoaffective, and affective-disorders. American Journal of Psychiatry 152 6 (1995) 856-861
14. Keefe R.S.E., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A., and HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research 81 1 (2006) 1-15
15. Kern R.S., Green M.F., Marshall B.D.J., Wirshing W.C., Wirshing D., McGurk S.R., Marder S.R., and Mintz J. Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. Schizophrenia Bulletin 25 2 (1999) 223-232
16. Krystal J.H., D'Souza D.C., Madonick S., and Petrakis I.L. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35 (1999) S35-S49
17. Lindenmayer J.P., Khan A., Iskander A., Abad M.T., and Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry 68 3 (2007) 368-379
18. Littrell K.H., Petty R.G., Hilligoss N.M., Peabody C.D., and Johnson C.G. Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment 21 4 (2001) 217-221
19. Petrakis I.L., Leslie D., Finney J.W., and Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. American Journal on Addictions 15 1 (2006) 44-49
20. Potvin S., Stip E., and Roy J.Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. International Clinical Psychopharmacology 18 3 (2003) 121-132
21. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 264 19 (1990) 2511-2518
22. Smelson D.A., Losonczy M.F., Davis C.W., Kaune M., Williams J., and Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry 47 7 (2002) 671-675
23. Stanniland C., and Taylor D. Tolerability of atypical antipsychotics. Drug Safety 22 (2000) 195-214
24. Stokes M.E., Davis C., and Koch G.G. Categorical Data Analysis using the SAS System (1995), SAS Institute Inc., Cary, NC
25. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., and Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29 1 (2003) 15-31
26. Swanson J., Estroff S., Swartz M., Borum R., Lachicotte W., Zimmer C., and Wagner R. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry 60 1 (1997) 1-22
27. Swanson J.W., Swartz M.S., and Elbogen E.B. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin 30 (2004) 3-20
28. Swartz M.S., Swanson J.W., Hiday V.A., Borum R., Wagner H.R., and Burns B.J. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 155 2 (1998) 226-231
29. Swartz M.S., Wagner H.R., Swanson J.W., Stroup T.S., McEvoy J.P., Canive J.M., Miller D.D., Reimherr F., McGee M., Kahn A., Van Dorn R.A., Rosenheck R.A., and Lieberman J.A. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease 194 (2006) 164-172
30. Swofford C.D., Kasckow J.W., Scheller-Gilkey G., and Inderbitzin L.B. Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research 20 (1996) 145-151
31. Tsuang J.W., Eckman T., Marder S., and Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients?. Journal of Clinical Psychopharmacology 22 6 (2002) 629-630
32. Van Dorn R.A., Mustillo S., Elbogen E.B., Dorsey S., Swanson J.W., and Swartz M.S. The effects of early sexual abuse on adult risky sexual behaviors among persons with severe mental illness. Child Abuse and Neglect 29 11 (2005) 1265-1279
33. Van Dorn R.A., Swanson J.W., Elbogen E.B., and Swartz M.S. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Mental Health Services Research 7 (2005) 123-134